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012.12.00Abstract Introduction: Gout is a form of inﬂammatory arthritis that is characterized by attacks of
active synovitis related to the presence of monosodium urate (MSU) crystals in the joints and per-
iarticular soft tissues.
Aim of the work: To establish the usefulness of ultrasonography (US) in diagnosing subclinical
gouty arthritis and to determinewhether there are sonographic features that are characteristic of gout.
Patients andmethods: We studied 20 patients known to be gouty (group 1), 20 patients with asymp-
tomatic hyperuricemia (AH) (group 2) and 20 controls (group 3) in a cross sectional study. Demo-
graphic, clinical and serological data were evaluated. Knee and 1st MTP joints were assessed by
musculoskeletal (US) to detect subclinical gouty arthritis.
Results: Clinical gouty arthritis was found in only (20%) in (group 1), but subclinical gouty arthri-
tis had been found in (75%) in (group1) and (25%) in (group 2). There were statistically signiﬁcant
differences between the examined groups regarding the presence of double contour (DC) sign
(p< 0.001), joint effusion (p= 0.04), serum uric acid (SUA) level (p< 0.001), diuretics use
(p< 0.001), allopurinol use (p< 0.001), also it was found that only SUA was the risk factor for
the occurrence of the double contour (DC) sign (p= 0.03) and cut-off value of SUA was 9.1 mg/dl
above which DC sign was detected.
Conclusion: Ultrasonography (US) is a useful tool to detect subclinical gouty arthritis; also serves
as a non-invasive, bedside and non-ionizing tool.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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31. Introduction
Gout is one of the commonest forms of inﬂammatory arthritis.
The prevalence appears to be rapidly increasingworldwide [1]. It
is mediated by the crystallization of uric acid within the
joints [2]. Urate crystals are deposited predominantly in theuction and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.
72 W. Gaber et al.superﬁcial portions of the articular cartilage. These characteris-
tic cartilaginous deposits are not readily demonstratedwith con-
ventional diagnostic imaging including roentgenography,
computed tomography (CT) or magnetic resonance imaging
(MRI) [3].
Gout occurs when too much uric acid builds up in the
blood and uric acid crystals precipitate in the cooler parts of
the body such as the joints of the feet. High levels of uric acid
may also build up as lumps under the skin called tophi or as
kidney stones. Uric acid is a waste product of the oxidation
of purines which are constituents of nucleic acids such as
DNA. Uric acid is normally excreted in the urine to maintain
a concentration of uric acid in the blood of approximately
4 mg/dl. When the concentration exceeds 7 mg/dl, crystals of
monosodium urate start to form in the tissues. This condition
is known as hyperuricemia [4].
Several British and American surveys have estimated the
prevalence of gout to be 2.6–8.4 per 1000 in adults, with the prev-
alence increasing with age to rates of 24 per 1000 in men and 16
per 1000 inwomen aged 65–74 years.Gout has a predilection for
the ﬁrst metatarsophalangeal joint (1st MTPJ), with as many as
50–70% of ﬁrst gout attacks occurring here [5].
The National Health and Nutrition Examination Survey
(NHANES) data from 2007 to 2008 showed a hyperuricemia
(serum urate P7 mg/dl) prevalence of 21.1% in men and
4.7% in women [6]. Most individuals with hyperuricemia,
however, do not develop gouty arthritis [7]. The reported
gouty arthritis prevalence in the 2007 to 2008 NHANES data
was 5.9% in men and 2% in women, with an overall preva-
lence of 3.9% (8.3 million adults) [6]. The risk of developing
gouty arthritis is dependent on the severity of hyperuricemia.
In the Normative Aging Study, healthy patients with serum ur-
ate levels P9 mg/dl upon entry into the study had a cumula-
tive incidence of acute ﬂares that reached 22% after 5 years,
whereas those with serum urate levels 67 mg/dl had an annual
incidence of only 0.5% [8]. In another study, the 5-year prev-
alence of gouty arthritis was 30% in individuals with serum ur-
ate levels >10 g/dl [9].
In patients with the very ﬁrst manifestations of gout, no
radiographic ﬁndings are present but for an increase in the soft
tissues. Typical plain radiographic features of chronic gout [10]
include visualization of tophi as soft-tissue or intraosseous
masses, and the presence of a nondemineralizing erosive
arthropathy with erosions that are well deﬁned with sclerotic
or overhanging margins [11].
The joint space is usually preserved until late in the disease
and other features such as periosteal new bone formation,
extra-articular erosions, intraosseous calciﬁcations, joint space
widening and subchondral collapse may be present [12–14].
Radiographic abnormalities are most frequently present in
the feet, particularly in the ﬁrst metatarsal phalangeal joint.
Radiographic damage is a late feature of chronic gout,
typically occurring 15 years after the onset of the disease,
and is virtually always present in patients with subcutaneous
tophi [14].
Over the past several years, there has been a growing inter-
est in musculoskeletal ultrasound (US) in rheumatology. US
visualizes tissues as acoustic reﬂections. Crystalline material re-
ﬂects US waves more strongly than the surrounding tissues,
such as unmineralized hyaline cartilage or synovial ﬂuid. This
enables distinction of monosodium urate (MSU) crystal depo-
sition from the less echogenic surrounding soft tissues. MSUcrystals are found in the cartilage, tendon sheaths, synovial
ﬂuid and subcutaneous tissue. US detects deposition of MSU
crystals on cartilaginous surfaces, as well as tophaceous mate-
rial and typical erosions. A hyperechoic, irregular band over
the superﬁcial margin of the articular cartilage, described as
a double contour sign or icing, is found exclusively in gouty
arthritis [3] and represents crystalline precipitates of MSU.
In addition, the presence of hypoechoic to hyperechoic inho-
mogeneous material surrounded by a small anechoic rim, rep-
resenting tophaceous material and erosions adjacent to
tophaceous material on US, are suggestive of the diagnosis
of gouty arthritis. US is superior in detecting changes of gouty
arthritis compared with other imaging modalities (magnetic
resonance imaging, plain X-ray scans, computed tomography
and three-dimensional rendering imaging) [15].
In contrast to gout, calcium pyrophosphate crystals tend to
aggregate in the centre of both hyaline and ﬁbrous cartilage. In
the hyaline cartilage, this material forms a layer that parallels
the bony cortex. Sonographically this appears as a hyperech-
oic, irregular line embedded in anechoic appearing hyaline car-
tilage. Chondrocalcinosis can thus be readily distinguished
from gout [16,17].
Recent studies into the pathophysiology of acute gout have
revealed that MSU, the crystalline form of uric acid, is recog-
nized by immune cells as a danger signal and can initiate an
inﬂammatory response. This response is orchestrated by the
intracellular pattern-recognition receptor NLRP3, which upon
exposure to MSU, forms a cytosolic multiprotein-complex
called the inﬂammasome, leading to the activation of cas-
pase-1. Caspase-1 then cleaves the highly pro-inﬂammatory
cytokines interleukin (IL)-1b and IL-18, leading to the secre-
tion of their biologically active forms and culminating in an
acute gouty attack [18].Aim of the present study was to evalu-
ate the diagnostic capability of ultrasonography in detecting
the subclinical gouty arthritis as a safe, easy and bedside diag-
nostic tool.2. Patients and methods
2.1. Patients
Forty male patients were consecutively recruited from the
Rheumatology department, Cairo and Fayoum University
hospitals. Half of them were fulﬁlling the ACR diagnostic cri-
teria of gout [19], none of them had chronic tophaceous gout
and the other 50% had asymptomatic hyperuricemia (AH)
only, also 20 controls with matched age and sex were enrolled.
All subjects were asked to complete a questionnaire on
demographics and medication use. Serum uric acid was as-
sessed for all subjects.
Subjectswere categorized as belonging to 1of 3 groups: (1) gout
(those meeting ACR clinical criteria), (2) AH (no gout per ACR
clinical criteria, UA levelP6.9 mg/dl), and (3) control (no gout,
UA level66.8 mg/dl). Informed consents were taken from the pa-
tients and the study was approved by the local ethics committee.
2.2. Exclusion criteria
1. Rheumatoid arthritis.
2. Seronegative spondyloarthritis.
3. Pseudo gout.
Figure 1 Plain X-ray of the left foot showing soft tissue edema
of the ﬁrst metatarsophalangeal joint (white arrow).
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5. History of severe trauma to the affected joint.
6. Malignancy.
2.3. US interpretation
All subjects subsequently underwent a structural musculoskel-
etal US evaluation of both knee joints (transverse suprapattel-
lar view of the femoral cartilage in maximal ﬂexion) and both
1st MTP joints (longitudinal dorsal and medial views) using a
12.5 MHz linear probe (Philips-ATL, HDI 5000, Philips,
Bothell, WA, USA).
US deﬁnitions described by the Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) Special
Interest Group were adopted for the study. Joint effusion
was recorded when anechoic or hypoechoic joint cavity widen-
ing was detected, while synovial hypertrophy was recognized
as the presence of abnormal hypoechoic or hyperechoic tissue
within the joint cavity. Additionally, hyperechoic enhance-
ment of the superﬁcial margin of the hyaline cartilage was re-
garded as a surrogate of MSU crystal deposition (double
contour sign), whereas inhomogeneous tendon and/or enthe-
seal thickening and intratendinous hyperechoic bands deﬁned
the presence of enthesopathy or tendinopathy. Erosion was
deﬁned as a deﬁnite cortical interruption with a step-down
contour defect in both longitudinal and transverse views
[20].
Statistical analysis: Computer software package SPSS 15
was used in the analysis, for quantitative variables, mean (as
a measure of central tendency), standard deviation (as measure
of variability) were presented. Frequencies and percentages
were presented for qualitative variables. ANOVA test was used
to estimate differences in quantitative variables. Chi-square
and Fisher-exact tests were used to estimate differences in
qualitative variables. Logistic regression analysis was used, P
Value <0.05 is signiﬁcant [21].Table 1 Demographics, clinical and laboratory data and managem
Gouty patients
(group 1) (20 patients
Clinical and demographic data
Age (mean ± SD) 58.6 ± 7.9
Arthritis in 1st MTP joints No. (%) 5/40 (12.5%)
Laboratory data
SUA (mean ± SD) 11.3 ± 1.8
Serum creatinine (mean ± SD) (mg/dl) 0.7 ± 0.3
Ultrasonography data
No. (%) of patients with double contour sign. 15 (75%)
No. (%)of patients with joint eﬀusion 9 (45%)
Treatment received
No. (%)of patients on diuretics 12 (60%)
No. (%)of patients on allopurinol 12 (60%)
No. (%) of patients on colchicine 13 (65%)
1st MTP: ﬁrst metatarsophalangeal, SUA: serum uric acid.
* Signiﬁcantly different at p< 0.05.
** Is signiﬁcantly different at p< 0.001.3. Results
Twenty male patients known to be gouty were examined in the
current study, with a mean age of 58.6 ± 7.9 years and mean
disease duration of 6.4 ± 2.3 years as well as 20 male patients
with asymptomatic hyperuricemia (AH) with a mean age of
59.5 ± 6.7 years and 20 controls with matched age and sex
with a mean age of 57.4 ± 6.2 years as shown in Table 1.
All of enrolled subjects gave history of knee osteoarthritis,
but clinically they had crepitus only, none of our patients had
tophi, renal stones or nephropathy, but ﬁve swollen and tender
1st MTP joints were found in 4/20 (20%) of patients in (group
1) and absent in (group 2 and 3); but musculoskeletal US
examination revealed MSU deposition in 15/20 (75%) of pa-
tients in (group 1) and 5/20 (25%) in (group 2). X-ray exami-
nation of the affected joints revealed no speciﬁc radiographic
ﬁndings for gouty arthritis except a mild increase in the soft tis-
sues in 1st MTP joint as shown in Fig. 1.ent strategy of the study groups.
)
AH patients
(group 2) (20 patients)
Control group
(group 3) (20 subjects)
P value
59.5 ± 6.7 57.4 ± 6.2 0.6
0 (0%) 0 (0%) 0.3
8.3 ± 1.5 4.5 ± 0.9 <0.001**
0.6 ± 0.2 0.4 ± 0.2 0.4
5 (25%) 0 (0%) <0.001**
3 (15%) 0 (0%) 0.04*
4 (20%) 2 (10%) 0.001**
3 (15%) 0 (0%) 0.001**
7 (35%) 0 (0%) 0.06
Figure 2 US longitudinal view of the knee joint; showing the
double contour (DC) sign (white arrow).
Figure 3 US longitudinal view of the knee joint; showing the
double contour (DC) sign (white arrow).
Figure 4 US longitudinal view of ﬁrst metatarsophalangeal
joint; showing joint effusion (white arrow).
Table 2 Shows that serum uric acid is the only risk factor for
occurrence of DC sign.
P value Odds ratio 95.0% C.I.
Age 0.6 1.1
SUA 0.03* 11.6 0.9–1.3
Diuretics intake 0.7 1.8
* Signiﬁcantly different at p< 0.05.
74 W. Gaber et al.Double contour sign as shown in Figs. 2 and 3 and effusion
as shown in Fig. 4 were detected by US and the results were
shown in Table 1, but neither joint erosion nor tophi were de-
tected by US. Also it was found that, the cut-off value for SUA
above which the DC sign was detected was 9.1 mg/dl. On cor-
relating the presence of the double contour sign to age, SUA
and intake of diuretics, it was found that only SUA was therisk factor of the occurrence of the double contour sign as
shown in Table 2. Also SUA level was signiﬁcantly higher in
patients with AH with DC sign in relation to patients with
AH and without DC sign (10.5 ± 1.3 mg/dl and
7.6 ± 0.6 mg/dl, respectively) (p= 0.005).
4. Discussion
In the present study clinical gouty arthritis was found in (20%)
of patients known to be gouty and absent in patients with AH;
but musculoskeletal US examination revealed DC sign in
(75%) of gouty patients and in (25%) of patients with AH
who showed signiﬁcantly higher SUA level; this matched the
results of Puig et al. (2008), who examined lower extremity
joints of AH patients by US and found DC sign in the knee
hyaline cartilage and the ﬁrst metatarsophalangeals, also
emphasized that US changes suggestive of gouty arthritis were
found in 25% of hyperuricemic individuals. These changes
were found exclusively in the hyperuricemic individuals but
not in their control group of normouricemic individuals [22].
Also the results in the present study coincides with the results
of a previous study that enrolled 50 male subjects, their knee
and 1st MTP joints were assessed by musculoskeletal ultra-
sound to detect the ‘‘double contour’’ sign as an evidence of
MSU crystal deposition. They found the DC sign in 29% of
AH subjects [23].
We found the double contour sign exclusively in patients
with hyperuricemia especially with SUA level P9.1 mg/dl
(P< 0.001). This band had a slightly irregular surface; that
was not seen in control patients. This sonographic ﬁnding
was consistent with older histopathological studies that
showed a particular predilection for uric acid to crystallize
on the surface of the hyaline cartilage [3]. This could be ex-
plained by the fact that; chondroitin sulphates and phosphati-
dylcholine, constituents of the hyaline cartilage, have been
reported to foster crystallization of uric acid in vitro [24].
The results of Neogi (2008), emphasized upon the useful-
ness of urate-lowering treatment in patients with clinical man-
ifestations of hyperuricemia such as gouty arthritis, but in
patients with AH it is still the object of several controversies
[25]. This could in part be related to the limited evidence about
the subclinical musculoskeletal involvement in asymptomatic
individuals with hyperuricemia [26]. In the present study, US
detected double contour sign and joint effusion in cases of
AH, this may increase the need for use of the urate lowering
therapy in this group of patients.
Double contour sign represents SUA crystal deposition in
the hyaline cartilages [24]. As conﬁrmation of the presence of
MSU in the hyaline cartilage, Thiele and Schlesinger (2010),
demonstrated the disappearance of the double contour sign
in patients with gout successfully treated with urate-lowering
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least 7 months [27]. This may strengthen the need for treatment
necessity in asymptomatic individuals with hyperuricemia and
indisputable US features of MSU crystal tissue deposition such
as the double contour sign or the presence of tophi [25].
In the current work diagnostic US detected double contour
sign in (75%) and in (25%) of gouty arthritis and AH patients
respectively, which was highly suggestive for the articular
deposition of monosodium urate crystals, depending on the re-
sults of Wright et al. (2007) and Gutierrez et al. (2009), who
emphasized that double contour sign had been described solely
in gout [28,29]. Despite the fact that; demonstrating the pres-
ence of MSU crystals in aspirated joint ﬂuid or tophus is con-
sidered the gold standard [30].
In conclusion; ultrasonography which is bedside, easy and a
safe radiological tool, can detect MSU deposition in patients
with AH, which necessitates the use of urate lowering drugs.
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